Jacc: heart failure paper reports promising findings of aquadex therapy in updated avoid-hf study analysis

Minneapolis, feb. 20, 2025 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today highlighted promising findings from an updated analysis of the avoid-hf study, recently published in the journal of the american college of cardiology: heart failure. the analysis, led by dr. sean p. pinney, chief of cardiology at mount sinai morningside and chief of nephrology at lenox hill hospital, dr. maria v. devita, provides new insights suggesting the potential benefits of aquadex® smartflow ultrafiltration therapy in managing heart failure. the analysis found that patients treated with aquadex therapy demonstrated a 60% reduction in heart failure events at 30 days compared to those receiving traditional iv diuretics.
NUWE Ratings Summary
NUWE Quant Ranking